Methylated 1,2-naphthoquinone derivative SJ006 as an inhibitor of human glucose 6-phosphate dehydrogenase in non-small cell lung cancer cell lines
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-21 23:49
摘要：
SJ006, a methylated 1,2-naphthoquinone derivative, has been identified as a potent inhibitor of glucose 6-phosphate dehydrogenase (G6PD) in non-small cell lung cancer (NSCLC) cell lines. The study demonstrates that SJ006 induces significant cytotoxicity and disrupts redox balance, leading to cell cycle arrest and apoptosis. Unlike traditional inhibitors, SJ006 does not affect G6PD expression levels, suggesting a novel mechanism of action. These findings position SJ006 as a promising candidate for further development in cancer therapy, particularly for NSCLC.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.5
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
SJ006 uniquely inhibited G6PD activity without altering its mRNA or protein expression.
SJ006 induced G2/M cell cycle arrest and triggered late apoptosis in NSCLC cells.
Molecular docking confirmed strong G6PD binding, indicating its potential as a targeted therapy.
真实性检查
否
AI评分总结
SJ006, a methylated 1,2-naphthoquinone derivative, has been identified as a potent inhibitor of glucose 6-phosphate dehydrogenase (G6PD) in non-small cell lung cancer (NSCLC) cell lines. The study demonstrates that SJ006 induces significant cytotoxicity and disrupts redox balance, leading to cell cycle arrest and apoptosis. Unlike traditional inhibitors, SJ006 does not affect G6PD expression levels, suggesting a novel mechanism of action. These findings position SJ006 as a promising candidate for further development in cancer therapy, particularly for NSCLC.